


02-27-02

CPA 1/1008

#8
JRP
5/7/02



CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

CHECK BOX, if applicable:
☐ DUPLICATE

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No. of Prior Application	17327CIPCPA(HL)
	First Named Inventor	Pacifici et al
	Examiner Name	Z. Fay
	Group Art Unit	1614
	Express Mail Label No.	EL897831442US

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d),
(continued prosecution application (CPA)) of prior application number 09/ 552,823,
filed on April 20, 2000, entitled USE OF RETINOID RECEPTOR ANTAGONISTS OR AGONISTS IN THE
TREATMENT OF CAPITACE BONE PATHOLOGIES

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

- ☒ Enter the unentered amendment previously filed on October 23, 2001 under 37 CFR 1.116 in the prior nonprovisional application.
- ☐ A preliminary amendment is enclosed.
- This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
 - ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:
.....
 - ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
- ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
- Information Disclosure Statement (IDS) is enclosed:
 - ☐ PTO-1449
 - ☐ Copies of IDS Citations


02/28/2002 JADD01 00000049 010885 09552823
01 FC:131 740.00 CH

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c) or (j))	6 -20* =	0	x \$ 18.00 =	\$ 0
	INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))	2 -3** =	0	x \$ 84.00 =	0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ 280.00 =	0
				BASIC FEE (37 CFR 1.16)	740.00
				Total of above Calculations =	
	Reduction by 50% for filing by small entity (Note 37 CFR 1.27).				
	* Reissue claims in excess of 20 and over original patent. ** Reissue independent claims over original patent.				TOTAL = 740.00

6. ☐ Small entity status: Applicant claims small entity status. See 37 CFR 1.27.
7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 01 - 0885:
- a. ☒ Fees required under 37 CFR 1.16.
- b. ☒ Fees required under 37 CFR 1.17.
- c. ☒ Fees required under 37 CFR 1.18.
8. ☐ A check in the amount of \$_____ is enclosed.
9. ☐ Payment by credit card. Form PTO-2038 is attached.
10. ☐ Applicant requests suspension of action under 37 CFR 1.103(b) for a period of _____ months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.
11. ☐ New Attorney Docket Number, if desired _____
(Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.)
12. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)
- b. ☒ Return Receipt Postcard (Should be specifically itemized, See MPEP 503)
13. ☐ Other: _____

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

14. NEW CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number or Bar Code Label		or <input type="checkbox"/> New correspondence address below			
		(Insert Customer No. or Attach bar code label here)			
Name					
Address					
City	State	Zip Code			
Country	Telephone	Fax			

15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name (Print I/Type)	Carlos A. Fisher
Signature	
Registration No. (Attorney/Agent)	36,510
Date	2/28/02

TECH CENTER 1600/2900

MAR 04 2002

RECEIVED



Docket No. 17327CIP(HL)
PATENT

#10/c

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Pacifici et al

Serial No. 09/552,823

Filed: April 20, 2000

For: USE OF RETINOID RECEPTOR
ANTAGONISTS OR AGONISTS IN THE
TREATMENT OF CARTILAGE AND BONE
PATHOLOGIES

Group Art Unit: 1614

Examiner: Fay, Z.

RECEIVED

MAR 04 2002

TECH CENTER 1600/2900

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231
Attention: Box AF

Dear Sir:

This correspondence is in reply to the Office Action mailed July 23, 2001. Applicants have carefully read the Office Action and have the following comments:

AMENDMENT

In the claims:

Kindly cancel claims 8- 11 without prejudice to their later presentation in this or a continuation or divisional application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail bearing in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on:

Date of Deposit: 10/23/01

Person making Deposit: Bonnie Ferguson

Signature: Bonnie Ferguson

Date of Signature: 10/23/01